OQL 036
Alternative Names: OQL-036Latest Information Update: 12 Jun 2023
At a glance
- Originator OnQuality Pharmaceuticals
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Erythrodysaesthesia
Most Recent Events
- 28 Apr 2023 The US FDA approves IND application for OQL 036 in Erythrodysaesthesia (Prevention)
- 28 Apr 2023 OnQuality plans a phase II trial Erythrodysaesthesia (Prevention) in 2023
- 26 Oct 2022 Pharmacodynamics data from a preclinical trial in Erythrodysaesthesia presented at the 34th EORTC-NCI-AACR Symposium (34th EORTC-NCI-AACR - 2022)